Nutrivert, Inc.
Nutrivert is dedicated to developing alternatives to antibiotics in livestock production, aiming to improve animal health and feed efficiency without relying on antibiotics. Their innovative products, such as Nutrivert LDPP, mimic bacterial cell wall components to promote growth and reduce inflammation, offering benefits for both animals and humans. The company also explores applications in human health, including protection against viral respiratory diseases like flu and COVID-19. Recognized for its innovation, Nutrivert has received awards such as the Cade Prize for Innovation and the Georgia Bio Best Startup.
Industries
Nr. of Employees
small (1-50)
Nutrivert, Inc.
St Louis, Missouri, United States, North America
Products
Medicated feed premix containing synthetic postbiotic analog
A thermostable, pelletable medicated feed premix designed for blending with livestock feed, sold in commercial package sizes (e.g., 50 lb / 20 kg) to improve feed efficiency and promote growth without antibiotic activity.
Human-use prophylactic drug candidates (preclinical)
Planned development of low-dose oral and slow-release injectable formulations intended to provide protection against influenza and potentially other respiratory viruses based on the same synthetic postbiotic mechanism.
Medicated feed premix containing synthetic postbiotic analog
A thermostable, pelletable medicated feed premix designed for blending with livestock feed, sold in commercial package sizes (e.g., 50 lb / 20 kg) to improve feed efficiency and promote growth without antibiotic activity.
Human-use prophylactic drug candidates (preclinical)
Planned development of low-dose oral and slow-release injectable formulations intended to provide protection against influenza and potentially other respiratory viruses based on the same synthetic postbiotic mechanism.
Services
Contracted development and oversight of cGMP manufacturing processes including selection/evaluation of FDA‑approved contract manufacturing sites.
Design and execution of in vivo studies in pigs and broiler chickens to evaluate growth promotion, feed conversion, and protection from respiratory viral diseases.
Contracted development and oversight of cGMP manufacturing processes including selection/evaluation of FDA‑approved contract manufacturing sites.
Design and execution of in vivo studies in pigs and broiler chickens to evaluate growth promotion, feed conversion, and protection from respiratory viral diseases.
Expertise Areas
- Antibiotic alternatives for livestock
- Preclinical animal efficacy testing and challenge models
- Postbiotic and immunomodulatory R&D
- Medicated feed premix formulation
Key Technologies
- Synthetic analogs of bacterial cell-wall components
- Postbiotic compounds
- NOD2 receptor agonism
- NF-κB pathway modulation
News & Updates
Winner of the 2024 AgTech Breakthrough of the Year
Recognized as a leading company in agricultural and food technology.
Best Startup at Georgia Bio 2023
Awarded for excellence in life sciences startups.
Winner of the 2020 Cade Prize for Innovation
Honored for innovative antibiotic replacement technologies.
Best Startup at Georgia Bio 2023
Recognized as a top startup in the life sciences sector.
Cade Prize for Innovation 2020
Awarded for innovative solutions in biotechnology.
Winner of the 2024 AgTech Breakthrough of the Year
Recognized as a leading company in agricultural and food technology.
Best Startup at Georgia Bio 2023
Awarded for excellence in life sciences startups.
Winner of the 2020 Cade Prize for Innovation
Honored for innovative antibiotic replacement technologies.
Best Startup at Georgia Bio 2023
Recognized as a top startup in the life sciences sector.
Cade Prize for Innovation 2020
Awarded for innovative solutions in biotechnology.